ATE494907T1 - Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten - Google Patents

Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten

Info

Publication number
ATE494907T1
ATE494907T1 AT08166335T AT08166335T ATE494907T1 AT E494907 T1 ATE494907 T1 AT E494907T1 AT 08166335 T AT08166335 T AT 08166335T AT 08166335 T AT08166335 T AT 08166335T AT E494907 T1 ATE494907 T1 AT E494907T1
Authority
AT
Austria
Prior art keywords
antigens
hsv
compositions containing
immunologically active
pharmaceutical compositions
Prior art date
Application number
AT08166335T
Other languages
English (en)
Inventor
David M Koelle
Zhi Liu
Lawrence Corey
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Application granted granted Critical
Publication of ATE494907T1 publication Critical patent/ATE494907T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AT08166335T 2002-07-18 2003-07-18 Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten ATE494907T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39679102P 2002-07-18 2002-07-18

Publications (1)

Publication Number Publication Date
ATE494907T1 true ATE494907T1 (de) 2011-01-15

Family

ID=30770951

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08166335T ATE494907T1 (de) 2002-07-18 2003-07-18 Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
AT03765758T ATE414176T1 (de) 2002-07-18 2003-07-18 Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03765758T ATE414176T1 (de) 2002-07-18 2003-07-18 Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene

Country Status (8)

Country Link
US (7) US7078041B2 (de)
EP (5) EP1523582B1 (de)
AT (2) ATE494907T1 (de)
AU (1) AU2003252052A1 (de)
CA (1) CA2492598C (de)
DE (2) DE60335755D1 (de)
DK (2) DK1523582T3 (de)
WO (1) WO2004009021A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509974A (en) * 1998-08-07 2003-10-31 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US20090220931A1 (en) * 2005-09-08 2009-09-03 Mologen Ag Functional in vitro immunoassay
US20070122415A1 (en) * 2005-11-29 2007-05-31 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compound and method for suppressing retroviral replication
WO2008011609A2 (en) 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
US9044447B2 (en) 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
US9782474B2 (en) 2010-11-24 2017-10-10 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
CN104321425B (zh) 2012-05-07 2018-08-10 株式会社Nkmax 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
WO2013168978A1 (ko) * 2012-05-07 2013-11-14 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
PL2850431T3 (pl) * 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
CN104694553B (zh) * 2013-12-05 2018-04-17 长春百克生物科技股份公司 生殖器疱疹疫苗
US20180320230A1 (en) * 2015-10-27 2018-11-08 Arizona Board Of Regents On Behalf Of Arizona State University High throughput identification of t-cell recognition antigens and epitopes
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
WO2019018796A1 (en) * 2017-07-21 2019-01-24 Fred Hutchinson Cancer Research Center VACCINE EPITOPES AGAINST HERPES SIMPLEX VIRUS RECOGNIZED SPECIFICALLY BY MEMORY T LYMPHOCYTES RESIDING IN FABRICS
NZ766453A (en) 2018-02-01 2022-02-25 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
EP3832178B1 (de) 2018-08-01 2024-05-01 Eagle Industry Co., Ltd. Gleitkomponente
EP3842673A4 (de) 2018-08-24 2022-05-04 Eagle Industry Co., Ltd. Gleitelement
KR102589959B1 (ko) 2018-11-30 2023-10-17 이구루코교 가부시기가이샤 슬라이딩 부품
JP7345998B2 (ja) 2018-12-21 2023-09-19 イーグル工業株式会社 摺動部品
US11933405B2 (en) 2019-02-14 2024-03-19 Eagle Industry Co., Ltd. Sliding component
EP4006368A4 (de) 2019-07-26 2023-08-16 Eagle Industry Co., Ltd. Gleitkomponente

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4429008B1 (en) 1981-12-10 1995-05-16 Univ California Thiol reactive liposomes
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS59116229A (ja) 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US7264817B1 (en) 1983-08-30 2007-09-04 Genentech, Inc. Immunogenic composition based on a truncated derivative of a membrane bound protein and process for making it
US4873088A (en) 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4618578A (en) * 1984-07-17 1986-10-21 Chiron Corporation Expression of glycoprotein D of herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4859587A (en) * 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5612041A (en) 1984-07-17 1997-03-18 Chiron Corporation Recombinant herpes simplex gD vaccine
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
TW232710B (de) * 1991-09-13 1994-10-21 American Cyanamid Co
KR100278157B1 (ko) * 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
CA2169748A1 (en) * 1993-08-20 1995-03-02 Anthony G. Dilella Hsv-2 ul26 gene, capsid proteins, immunoassays and protease inhibitors
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
GB9325496D0 (en) * 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995018148A1 (en) * 1993-12-28 1995-07-06 Chiron Mimotopes Pty Ltd T-cell epitopes
EP0772619B2 (de) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatorische oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP0871747A1 (de) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunstimulierung vermittelt durch genmodifizierte dendritische zellen
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5958895A (en) * 1996-10-23 1999-09-28 American Home Products Corporation DNA vaccines for herpes simplex virus
EP0948508A4 (de) * 1996-11-04 2001-11-07 Smithkline Beecham Corp Kodierungssequenzen vom herpes-simplex-virus typ 2
NZ509974A (en) * 1998-08-07 2003-10-31 Univ Washington Immunological herpes simplex virus antigens and methods for use thereof
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
JP2003512305A (ja) * 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
US6375652B1 (en) * 2000-05-04 2002-04-23 Brymill Corporation Cutaneous cryosurgical clamp
DE60125537D1 (de) * 2000-06-29 2007-02-08 Corixa Corp Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2002056828A2 (en) * 2000-11-29 2002-07-25 University Of Rochester Helper virus-free herpes virus amplicon particles and uses thereof
US8092791B2 (en) * 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
CA2454750C (en) * 2001-07-31 2012-09-18 David M. Koelle Immunologically significant herpes simplex virus antigens and methods for using same
US20030219448A1 (en) * 2002-05-24 2003-11-27 Cedars-Sinai Medical Center Peptide epitope-based vaccine for treating herpes simplex virus infections and related diseases

Also Published As

Publication number Publication date
US9138473B2 (en) 2015-09-22
WO2004009021A2 (en) 2004-01-29
DE60324678D1 (de) 2008-12-24
EP2263686B1 (de) 2012-12-26
EP1523582A2 (de) 2005-04-20
EP2316479B8 (de) 2015-03-18
EP1523582B1 (de) 2008-11-12
US7431934B2 (en) 2008-10-07
DK1523582T3 (da) 2009-03-02
US7078041B2 (en) 2006-07-18
EP1523582A4 (de) 2007-02-07
EP2316479A2 (de) 2011-05-04
WO2004009021A3 (en) 2004-06-03
DK2011510T3 (da) 2011-03-28
US20130011425A1 (en) 2013-01-10
US20040072152A1 (en) 2004-04-15
EP2011510A3 (de) 2009-04-08
EP2011510B1 (de) 2011-01-12
EP2316479B1 (de) 2014-12-03
EP2011510A2 (de) 2009-01-07
EP2316479A3 (de) 2011-07-06
CA2492598A1 (en) 2004-01-29
AU2003252052A8 (en) 2004-02-09
AU2003252052A1 (en) 2004-02-09
US8197824B2 (en) 2012-06-12
DE60335755D1 (de) 2011-02-24
EP2865386A1 (de) 2015-04-29
US20090148468A1 (en) 2009-06-11
CA2492598C (en) 2013-12-17
EP2263686A1 (de) 2010-12-22
ATE414176T1 (de) 2008-11-15
EP2865386B1 (de) 2017-07-05
US9675688B2 (en) 2017-06-13
US20160095918A1 (en) 2016-04-07
US20060216304A1 (en) 2006-09-28
US20110135687A1 (en) 2011-06-09
US20130189294A1 (en) 2013-07-25
US7666434B2 (en) 2010-02-23

Similar Documents

Publication Publication Date Title
ATE494907T1 (de) Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
NO20021479D0 (no) Immunologiske signifikante herpes simplex virus antigener og metoder for å identifisere og å bruke dem
Joshi et al. Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches
AR020134A1 (es) Antigenos inmunologicos contra el virus herpes simplex y metodos para el uso de los mismos
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
WO2001082963A3 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
RU2324493C2 (ru) Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
WO2023147092A3 (en) Coronavirus vaccine
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
HUP9904171A2 (hu) A ragadós száj- és körömfájás vírusok immunogén peptidjei
Carneiro et al. Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis
MXPA02010173A (es) Antigenos de leishmania para utilizarse en la terapia y el diagnostico de leishmaniasis.
EA200301125A1 (ru) Вакцины, включающие в качестве адъюванта интерферон типа i, и связанные с этим способы
YU99603A (sh) Geni koji su povezani sa virulencijom parazita laišmanije
CN101977930B (zh) 含核糖体蛋白质提取物（RPE)和任选的促Th1佐剂的疫苗
Strahan et al. V-REPP and plaques VZV
Kumar et al. Role of Vaccines on Human Health-A Review
AU4300700A (en) Inactivated cytokines for immunisation
Dube et al. Kala-azar: The immunological consequences and feasibility of vaccination
Thomson IMMUNOLOGICAL AND PROTECTIVE RESPONSES TO A HERPES SIMPLEX VIRUS SUBUNIT VACCINE IN A LABIAL INFECTION MODEL IN MICE.
RU98117675A (ru) Лекарственный состав с иммуномодуляторным действием, содержащий пептиды и вспомогательные средства

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties